Enlivex Therapeutics Ltd. (FRA:1BT)

Market Cap	184.02M
Revenue (ttm)	n/a
Net Income (ttm)	-10.83M
Shares Out	n/a
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	0.7050
Previous Close	0.6900
Day's Range	0.7050 - 0.7050
52-Week Range	0.5900 - 1.7100
Beta	n/a
RSI	45.62
Earnings Date	Mar 30, 2026

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 71
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1BT

Financial Performance

Financial numbers in USD